Please assess the completion status of the following clinical trial:

Trial Title: A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Aged ≥ 12 years and \< 17 years;~* BMI ≥ the 95th percentile, with documented history of failure to lose sufficient weight or failure to maintain weight loss in a lifestyle modification program;~* If female, must be using adequate contraception, defined as double barrier methods, stable hormonal contraception plus single barrier method, tubal ligation, or abstinence.~Exclusion Criteria:~* Type 1 diabetes;~* Congenital heart disease; clinically significant ECG abnormality;~* Clinically significant physical exam, vital signs, or laboratory abnormality; clinically significant hepatic or renal disease;~* Estimated Glomerular Filtration Rate (GFR; Schwartz formula) \< 60 mL/minute;~* Clinically significant thyroid dysfunction as evidenced by signs, symptoms, or thyroid stimulating hormone (TSH) \> 1.5 x Upper Limit of Normal;~* Obesity of known genetic or endocrine origin;~* History of bipolar disorder or psychosis, depression of moderate or greater severity, or presence or history of suicidal behavior or active suicidal ideation;~* Recent weight instability, or prior bariatric surgery;~* History of glaucoma or increased intraocular pressure;~* Current smoker or smoking cessation within 3 months of screening;~* Currently taking or plan on taking any of following medications during the study:~  * Anticonvulsants used for treatment of seizure disorder, including barbiturates, benzodiazepines, gamma-aminobutyric acid (GABA) analogues, hydantoins, phenyltriazines, succinimides, and other agents (valproic acid and its derivatives, carbamazepine and its derivatives, zonisamide, and felbamate);~ * Tricyclic antidepressants, monoamine oxidase inhibitors (MAOIs), lithium, levodopa, and dopamine receptor agonists;~ * Carbonic anhydrase inhibitors;~ * Insulin, Sulfonylureas (SFUs), glucagon-like peptide -1 (GLP-1) agonists, sodium glucose transporter-1 (SGLT-1), and SGLT-2 inhibitors;~ * Chronic systemic steroids (i.e. glucocorticoids, anabolic steroids) other than oral contraceptives;~ * Treatment for hyperactivity disorder; or~ * Over the counter, prescription medications, herbal agents and dietary supplements used with the intention to lose body weight.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- VI-0521 Mid Dose (Phentermine 7.5 mg +Topiramate 46 mg) (Type: EXPERIMENTAL): Weeks 1-2: VI-0521 (Phentermine 3.75 mg + Topiramate 23 mg) oral capsule, once daily; Weeks 3-56: VI-0521 (Phentermine 7.5 mg + Topiramate 46 mg) oral capsule, once daily
- VI-0521 Top Dose (Phentermine 15 mg + Topiramate 92 mg) (Type: EXPERIMENTAL): Weeks 1-2: VI-0521 (Phentermine 3.75 mg + Topiramate 23 mg) oral capsule, once daily; Weeks 3-12: VI-0521 (Phentermine 7.5 mg + Topiramate 46 mg) oral capsule, once daily; Weeks 13-14: VI-0521 (Phentermine 11.25 mg + Topiramate 69 mg) oral capsule, once daily; Weeks 15-56: VI-0521 (Phentermine 15 mg + Topiramate 92 mg) oral capsule, once daily
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will receive placebo oral capsule, once daily for up to 56 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).